SCHEMBL2907131

SCHEMBL2907131

Cc1[nH]c(=O)c(C)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 5/20 0.41
GRIN3B O60391 5/20 0.41
GRIN1 Q05586 5/20 0.41
GRIN2A Q12879 5/20 0.41
GRIN2B Q13224 5/20 0.41
GRIN2C Q14957 5/20 0.41
GRIN3A Q8TCU5 5/20 0.41
HSD17B10 Q99714 3/20 0.41
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
BRD4 O60885 1/20 0.41
PDE3B Q13370 3/20 0.40
PDE3A Q14432 3/20 0.40
ATAD2 Q6PL18 2/20 0.38
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.35
BCHE P06276 1/20 0.34
CES1 P23141 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249225 0.83 PDE3B (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27271864 0.81 HSD17B10 (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3123895 0.77 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15478582 0.77 HSD17B10 (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1738089 0.76 GRIN2D (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3084659 0.73 BRD4 (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21798393 0.73 KDM4E (0.67) HSD17B10HPGDKDM4EGAAPOLB
SCHEMBL5902557 0.73 GAA (0.54) HSD17B10HPGDKDM4EGAABRD4
SCHEMBL5091203 0.73 KDM4E (0.58) HSD17B10HPGDKDM4EGAAPDE3B
SCHEMBL7121819 0.71 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 GRIN2D 1306/4885GRIN3B 1014/4885GRIN1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.